Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2026 Vol. 4 > No. 2 > 100204
Next Article Previous Article
COMMENTARY   Open Access     Cite

Revisiting RNA in immunity: SARS-CoV-2 mRNA vaccine-based strategy for cancer immune response

  • 1.

    Precision Radiation in Oncology Key Laboratory of Sichuan Province, Radiotherapy Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, China

  • 2.

    The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu 610051, China

  • 3.

    School of Medicine, Southwest University of Science and Technology, Mianyang 621010, China

  • 4.

    Department of Institute of Preventive Medicine, Air Force Medical University, Xi'an 710032, China

  • 5.

    NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, Mianyang 621099, China

More Information
The Innovation Medicine  4(2),  https://doi.org/10.59717/j.xinn-med.2026.100204  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Old L.J., Clarke D.A. and Benacerraf B. (1959). Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 184:291−292. DOI:10.1038/184291a0

    View in Article CrossRef Google Scholar

    [2] Lin M.J., Svensson-Arvelund J., Lubitz G.S., et al. (2022). Cancer vaccines: The next immunotherapy frontier. Nat. Cancer 3:911−926. DOI:10.1038/s43018-022-00418-6

    View in Article CrossRef Google Scholar

    [3] Verbeke R., Hogan M.J., Loré K., et al. (2022). Innate immune mechanisms of mRNA vaccines. Immunity 55:1993−2005. DOI:10.1016/j.immuni.2022.10.014

    View in Article CrossRef Google Scholar

    [4] Grippin A.J., Marconi C., Copling S., et al. (2025). SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647:488−497. DOI:10.1038/s41586-025-09655-y

    View in Article CrossRef Google Scholar

    [5] Miao L., Li L., Huang Y., et al. (2019). Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37:1174−1185. DOI:10.1038/s41587-019-0247-3

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Li L., Yan T., Zhou J., et al. (2026). Revisiting RNA in immunity: SARS-CoV-2 mRNA vaccine-based strategy for cancer immune response. The Innovation Medicine 4:100204. https://doi.org/10.59717/j.xinn-med.2026.100204
    Li L., Yan T., Zhou J., et al. (2026). Revisiting RNA in immunity: SARS-CoV-2 mRNA vaccine-based strategy for cancer immune response. The Innovation Medicine 4:100204. https://doi.org/10.59717/j.xinn-med.2026.100204

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(1266) PDF downloads(485)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.